October 2023, Essentia Biosciences completed the angel round of financing. From 2022 to 2023, Essentia Biosciences has successively completed angel rounds and angel+ rounds of financing, with a total amount of tens of millions of RMB in all. Investors have included YuanBio Venture Capital, New Aerotropolis Fund, Yiyuan Investment, Beiyang Haitang, etc.
This round of funds will be mainly used to accelerate the construction of core pipeline GMP production lines, implementation of production processes, and promote preclinical research.
Essentia Biosciences’s key direction is to treat diabetes through islet cells differentiated from pluripotent stem cells. Potential indications include pancreatic damage, kidney damage, etc. Essentia Biosciences has developed three candidate pipelines in this direction.
- The first pipeline is the pluripotent stem cell islet differentiation pipeline ESN5800, which can achieve the therapeutic purpose of regenerating islets through clinical transplantation;
- The second pipeline is a universal (low immunogenicity) pluripotent stem cell islet differentiation project, which mainly solves the problem of islet The long-term and effectiveness issues of transplantation are to avoid immune rejection to the greatest extent and achieve large-scale production of “off-the-shelf regenerated islets”;
- The third is a cutting-edge exploration pipeline combining medicine and machinery to produce islet cell products combined with biological materials.
Research and development was officially launched in March 2022. The verification of the technical route of the first drug pipeline “ESN5800” has been completed by now. As announced by Essentia Biosciences, the core technical indicators have reached the top international level.
About Essentia Biosciences
Essentia Biosciences is a high-tech enterprise specializing in pluripotent stem cell drugs, focusing on the research and development and industrialization of pancreatic islet-oriented drugs. It has established R&D laboratories in Beijing, China and Cambridge, England. The core team is composed of young talents from Cambridge University, Oxford University, Peking University and other universities.https://essentiabiosciences.com